
    
      This is a randomized, double-blind, placebo-controlled, three-period cross-over study in
      asthma patients. The study will consist of a screening epoch, followed by a treatment epoch
      which consists of three treatment periods, and will conclude with an end of study epoch.

      Each subject will be assigned to 1 of 6 treatment sequences and will sequentially receive the
      investigational products and placebo during the trial.
    
  